Pharmahungary

Pharmahungary Group is a unique hybrid entity combining a full-service Contract Research Organization (CRO) with an internal biotech R&D arm. Its core expertise lies in complex preclinical models, particularly in cardiovascular and metabolic diseases, and in managing niche clinical trials for medical devices and sensitive populations. The company is advancing a pipeline of diagnostic and therapeutic projects, supported by proprietary bioinformatics tools, and is led by a founder with recognized scientific excellence. Its business model generates service revenue while seeking partnership deals for its proprietary assets.

Integrated preclinical platforms for cardiovascular and metabolic diseases, from cellular assays to custom large animal models (e.g., porcine, minipig). Proprietary bioinformatics/AI tools for target prediction (miRNAtarget), adverse event prediction (Vigilace), and image analysis (InfarctSizeAI). Vezics platform for exosome isolation.

As a CRO, competes with large global players (Charles River, Labcorp) and niche preclinical specialists, differentiating via deep cardiovascular/metabolic expertise and custom models. As a biotech, its early-stage miRNA and diagnostic projects compete with numerous other early-stage platforms, where success depends on unique data and validation.